 WARREN, N.J., March 25, 2021 GLOBE NEWSWIRE -- Aquestive Therapeutics, Inc. NASDAQ: AQST, a pharmaceutical company focused on developing and commercializing differentiated products that address patients unmet needs and solve therapeutic problems, will provide later this morning an in-depth overview of its systemic epinephrine drug delivery program combining its novel prodrug technology and its PharmFilm technology. At the RD event, the management team and KOLs will share an extensive review of the science, clinical results, and development strategy associated with two prodrug candidates in development for the treatment of allergic reactions including anaphylaxis. Aquestive has submitted multiple U.S. and foreign patent applications that cover the technology and formulations for its two prodrug candidates, AQST-108 and AQST-109. If granted, Aquestive anticipates patent protection for both drug candidates through at least 2037. 